Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Using Topology To Revolutionize Atrial Tachycardia Treatment

Project description

Innovative diagnostic tool finds optimal ablation target for atrial tachycardia

Atrial tachycardia (AT) is a heart rhythm disorder characterised by rapid beating of the upper chambers, causing palpitations, shortness of breath or dizziness. Timely treatment is essential to manage symptoms and prevent heart failure, typically through ablation therapy. The ERC-funded AT-TOP project aims to validate an innovative diagnostic tool known as Directed Graph Mapping (DGM). DGM leverages mathematical and topological methods to accurately classify and analyse AT, enabling the prediction of optimal ablation targets. DGM can anticipate hidden ATs that may arise during treatment, which can be prevented by selecting the correct ablation line, thereby significantly reducing procedure time. A prospective study involving 15 hospitals is planned to validate the tool, paving the way for its integration into clinical practice.

Objective

Atrial tachycardia (AT) is a prevalent form of supraventricular tachycardia that can have detrimental impacts on a person's health. The complexity of anatomical reentry patterns and unclear nomenclature hinders precise diagnosis of AT and makes optimal treatment challenging and error prone. Suboptimal treatment can result in severe outcomes such as heart failure, stroke, and pacemaker implantation due to overablation-induced atrial dysfunction.

In this proposal, we introduce a diagnostic tool called Directed Graph Mapping (DGM), which offers a unique classification system based on clear and precise mathematical criteria using topological principles, allowing for the accurate diagnosis and differentiation of various types of AT. DGM can automatically analyze a given case of AT, providing consistent and reliable results, paving the way for the optimization of the ablation strategy. DGM can not only diagnose the current AT but also predict hidden slower ATs, which might appear depending on the chosen ablation target. By being able to predict the hidden ATs, we can revolutionize the treatment of ATs, as these hidden ATs can be treated already after the measurement of the first anatomical map. Therefore, our tool holds the potential to significantly expedite the ablation procedure.

We propose to conduct a prospective study involving a minimum of 15 hospitals in Belgium that specialize in AT ablations to further validate the effectiveness and sustainability of our proposed solution while involving a broad range of electrophysiologists. We aim to publish our results in a high-impact journal.

We secured the intellectual property rights of our proof-of-concept through two patents, and by discussing with electrophysiologists, we learned that their interest in DGM influences mapping systems. If they recognize the value of DGM for treating AT, mapping companies may adopt the technology through a licensing agreement, which is the final goal of this proposal.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

UNIVERSITEIT GENT
Net EU contribution
€ 150 000,00
Address
SINT PIETERSNIEUWSTRAAT 25
9000 Gent
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)